SCHEMBL6880252

SCHEMBL6880252

CCOC(=O)c1cnc(SC)nc1Oc1ccccc1C

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.60
NPSR1 Q6W5P4 3/20 0.60
POLB P06746 2/20 0.60
TDP1 Q9NUW8 2/20 0.60
MAPT P10636 5/20 0.56
HTT P42858 2/20 0.56
KMT2A Q03164 2/20 0.55
HPGD P15428 2/20 0.55
MAPK1 P28482 2/20 0.55
LMNA P02545 2/20 0.55
SMN1; SMN2 Q16637 1/20 0.53
MEN1 O00255 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
SYK P43405 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31467164 0.87 ALDH1A1 (0.69) ALDH1A1NPSR1POLBTDP1MAPT
SCHEMBL11009450 0.87 ALDH1A1 (0.69) ALDH1A1NPSR1POLBTDP1MAPT
SCHEMBL6880096 0.86 RXFP1 (0.49) ALDH1A1NPSR1POLBTDP1MAPT
Guaiacol SCHEMBL6878387 0.85 ALDH1A1 (0.54) ALDH1A1NPSR1POLBTDP1MAPT
2-Chlorophenol SCHEMBL6877895 0.84 MAPT (0.59) ALDH1A1NPSR1POLBTDP1MAPT
Phenol SCHEMBL6873017 0.83 ALDH1A1 (0.65) ALDH1A1NPSR1POLBTDP1MAPT
SCHEMBL31148410 0.82 MEN1 (0.61) ALDH1A1NPSR1POLBTDP1MAPT
SCHEMBL3278294 0.82 MEN1 (0.61) ALDH1A1NPSR1POLBTDP1MAPT
SCHEMBL15584081 0.81 ALDH1A1 (0.63) ALDH1A1NPSR1POLBTDP1MAPT
SCHEMBL6876018 0.81 CYP1A2 (0.61) ALDH1A1POLBMAPTHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6787539-B2 HAS ACTIVITY AS AN ANTAGONIST TO NEUROKININ 1 RECEPTORS; FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA (BPH) HOFFMANN-LA ROCHE INC. 2004-09-07 US disclosed
EP-1339698-A2 PYRIMIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-09-03 EP disclosed
US-20020099207-A1 2,4,5,-trisubstituted pyrimidine derivatives HOFFMANN-LA ROCHE INC. 2002-07-25 US disclosed
WO-2002042280-A2 PYRIMIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099207-A1 2,4,5,-trisubstituted pyrimidine derivatives TACR1, TACR2, P2RY2 ALDH1A1 1117/4885NPSR1 6/4885POLB 3098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.